Professor of Urology, University Tex Houston
Urology
Dr. Curtis A. Pettaway, MD
|
|
Give Review
Curtis A. Pettaway practices Urology. He went to Temple University School of Medicine. He received awards:"Top Doctors:SE Texas". Curtis Pettaway is a published physician as well. He has 76 publications published. The latest was: Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien Sys... Curtis A. Pettaway accepts Medicare payments and is listed with Medicare.gov.
Publications
- Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien Sys...
- Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes.
- Robotic or open radical Prostatectomy after previous open surgery in the pelvic region.
- Penile Cancer: New Insights into the "Way Forward" for this Rare Disease.
- Prognostic Factors Influencing Survival from Regionally Advanced Squamous Cell Carcinoma of the Penis After Preoperative Chemotherapy.
- A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate Cancer.
- Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate Cancer clinic.
- Generalizability of established prostate Cancer risk variants in men of African ancestry.
- Early experience of robotic-assisted inguinal lymphadenectomy: review of surgical outcomes relative to alternative approaches.
- Management of Advanced Primary Urethral Carcinomas.
- Epidermal Growth Factor Receptor-Targeted Therapy in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.
- Genome-wide association of body fat distribution in african ancestry populations suggests new Loci.
- Treatment regret and quality of life following radical Prostatectomy.
- Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with Penile carcinoma.
- A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry.
- Integrated Hedgehog signaling is induced following castration in human and murine prostate Cancers.
- Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with Urethral carcinomas referred to medical oncologists(☆).
- Is transureteroureterostomy performed during multi-organ resection for non-urothelial malignancy safe and effective?
- Correction: identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry.
- Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry.
- Penoscrotal Extramammary Paget's Disease: The University of Texas M. D. Anderson Cancer Center Contemporary Experience.
- Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.
- Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment.
- Benign prostatic hyperplasia: racial differences in treatment patterns and prostate Cancer prevalence.
- Therapeutic strategies for advanced Penile carcinoma.
- Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile Cancer: a phase II study.
- Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile Cancer.
- Long-term quality of life after radical Prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial.
- Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
- Association between lymph node density and disease specific survival in patients with penile Cancer.
- The effects of a presurgical stress management intervention for men with prostate Cancer undergoing radical prostatectomy.
- Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate Cancer.
- Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate Cancer.
- Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate Cancer risk in African American familial and sporadic cases.
- Malignant transformation of Testicular teratoma: a chemoresistant phenotype.
- The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate Cancer patients.
- Saturated fat intake predicts biochemical failure after Prostatectomy.
- Prostate Cancer in Mexican-Americans: identification of risk factors.
- Treatment outcomes of small cell carcinoma of the Prostate: a single-center study.
- Organ preservation for muscle-invasive Bladder cancer by transurethral resection.
- Ability of clinical grade to predict final pathologic stage in upper Urinary tract transitional cell carcinoma: implications for therapy.
- Salvage prostatectomy with Bladder neck closure, continent catheterizable stoma and Bladder augmentation: feasibility and patient reported continence outcomes at 32 mo...
- Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile Cancer: results with pathological correlation.
- Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic Penile squamous cell carcinoma.
- Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate Cancer.
- Prostate Cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
- Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience.
- Comparative outcomes of Bladder cancer.
- African-American men with nonpalpable prostate Cancer exhibit greater tumor volume than matched white men.
- Neuropilins in neoplasms: expression, regulation, and function.
- Cystoprostatectomy for effective palliation of symptomatic Bladder invasion by prostate cancer.
- Obesity, weight gain, and risk of biochemical failure among prostate Cancer patients following prostatectomy.
- What's new in the management of penile Cancer?
- Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate Cancer.
- Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate Cancer in nude mice.
- Expression of interleukin-8 gene in radical Prostatectomy specimens is associated with advanced pathologic stage.
- Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience.
- Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate Cancer.
- Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate Cancer.
- Androgen receptor polymorphisms and risk of biochemical failure among Prostatectomy patients.
- Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate Cancer.
- Enhanced invasion of hormone refractory prostate Cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
- The role of lymphadenectomy in penile Cancer.
- Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha.
- Evidence that transfer of functional p53 protein results in increased apoptosis in prostate Cancer.
- Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate Cancer.
- Natural history, management, and surveillance of recurrent squamous cell Penile carcinoma: a risk-based approach.
- Clinical features and treatment outcome of Hispanic men with prostate Cancer following external beam radiotherapy.
- Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the Bladder?
- The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate Cancer a...
- Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate Cancer xenografts via induction of endothelial...
- Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features.
- Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience.
- Interest in genetic prostate Cancer susceptibility testing among african American men.
- Local recurrence map to guide target volume delineation after radical Prostatectomy.
Schools
Temple Univ Sch Of Med
University Tex Sw
MD Anderson Cancer Center University Tex
Procedures Preformed
- Cystometry
- Cystourethroscopy and TransUrethral Resection of Bladder Neck
- Kidney and Ureter Removal
- Kidney Stone Removal (Percutaneous Nephrostolithotomy, PCNL)
- View All
Conditions Treated
- Balanoposthitis
- Bladder Cancer
- Bladder Infection
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- First Health (Coventry Health Care) PPO
- Golden Rule
- Health Alliance
- HealthSmart
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MHealth Insured
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Top Doctors:SE Texas
Education
-
University of Texas MD Anderson Cancer Center -
Temple University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1942306030 | |
| NPPES Provider LastName | PETTAWAY | |
| NPPES Provider FirstName | CURTIS | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 122.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1942306030 |
| Last Name Of The Provider | PETTAWAY |
| First Name Of The Provider | CURTIS |
| View All |
Similar Doctors
|
Dr. Lei Chu, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Russel H. Williams, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Douglas S. Dow, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ramesh Krishnan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Laneri Jr., MD |
|
|
Dr. Arnold B. Skor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Coburn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alvin C. Goh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter C. Black, MD |